Antibiofilm peptides: Potential as broadspectrum agents

Daniel Pletzer, Robert Hancock

Research output: Contribution to journalReview article

59 Citations (Scopus)

Abstract

The treatment of bacterial diseases is facing twin threats, with increasing bacterial antibiotic resistance and relatively few novel compounds or strategies under development or entering the clinic. Bacteria frequently grow on surfaces as biofilm communities encased in a polymeric matrix. The biofilm mode of growth is associated with 65 to 80% of all clinical infections. It causes broad adaptive changes; biofilm bacteria are especially (10-to 1,000-fold) resistant to conventional antibiotics and to date no antimicrobials have been developed specifically to treat biofilms. Small synthetic peptides with broad-spectrum antibiofilm activity represent a novel approach to treat biofilm-related infections. Recent developments have provided evidence that these peptides can inhibit even developed biofilms, kill multiple bacterial species in biofilms (including the ESKAPE [Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species] pathogens), show strong synergy with several antibiotics, and act by targeting a universal stress response in bacteria. Thus, these peptides represent a promising alternative treatment to conventional antibiotics and work effectively in animal models of biofilm- associated infections.

LanguageEnglish
Pages2572-2578
Number of pages7
JournalJournal of bacteriology
Volume198
Issue number19
DOIs
Publication statusPublished - 1 Jan 2016
Externally publishedYes

ASJC Scopus subject areas

  • Microbiology
  • Molecular Biology

Cite this

Pletzer, Daniel ; Hancock, Robert. / Antibiofilm peptides : Potential as broadspectrum agents. In: Journal of bacteriology. 2016 ; Vol. 198, No. 19. pp. 2572-2578.
@article{09ce827e838140edb5de9aa7839e3d1d,
title = "Antibiofilm peptides: Potential as broadspectrum agents",
abstract = "The treatment of bacterial diseases is facing twin threats, with increasing bacterial antibiotic resistance and relatively few novel compounds or strategies under development or entering the clinic. Bacteria frequently grow on surfaces as biofilm communities encased in a polymeric matrix. The biofilm mode of growth is associated with 65 to 80{\%} of all clinical infections. It causes broad adaptive changes; biofilm bacteria are especially (10-to 1,000-fold) resistant to conventional antibiotics and to date no antimicrobials have been developed specifically to treat biofilms. Small synthetic peptides with broad-spectrum antibiofilm activity represent a novel approach to treat biofilm-related infections. Recent developments have provided evidence that these peptides can inhibit even developed biofilms, kill multiple bacterial species in biofilms (including the ESKAPE [Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species] pathogens), show strong synergy with several antibiotics, and act by targeting a universal stress response in bacteria. Thus, these peptides represent a promising alternative treatment to conventional antibiotics and work effectively in animal models of biofilm- associated infections.",
author = "Daniel Pletzer and Robert Hancock",
year = "2016",
month = "1",
day = "1",
doi = "10.1128/JB.00017-16",
language = "English",
volume = "198",
pages = "2572--2578",
journal = "Journal of Bacteriology",
issn = "0021-9193",
publisher = "American Society for Microbiology",
number = "19",

}

Antibiofilm peptides : Potential as broadspectrum agents. / Pletzer, Daniel; Hancock, Robert.

In: Journal of bacteriology, Vol. 198, No. 19, 01.01.2016, p. 2572-2578.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Antibiofilm peptides

T2 - Journal of Bacteriology

AU - Pletzer, Daniel

AU - Hancock, Robert

PY - 2016/1/1

Y1 - 2016/1/1

N2 - The treatment of bacterial diseases is facing twin threats, with increasing bacterial antibiotic resistance and relatively few novel compounds or strategies under development or entering the clinic. Bacteria frequently grow on surfaces as biofilm communities encased in a polymeric matrix. The biofilm mode of growth is associated with 65 to 80% of all clinical infections. It causes broad adaptive changes; biofilm bacteria are especially (10-to 1,000-fold) resistant to conventional antibiotics and to date no antimicrobials have been developed specifically to treat biofilms. Small synthetic peptides with broad-spectrum antibiofilm activity represent a novel approach to treat biofilm-related infections. Recent developments have provided evidence that these peptides can inhibit even developed biofilms, kill multiple bacterial species in biofilms (including the ESKAPE [Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species] pathogens), show strong synergy with several antibiotics, and act by targeting a universal stress response in bacteria. Thus, these peptides represent a promising alternative treatment to conventional antibiotics and work effectively in animal models of biofilm- associated infections.

AB - The treatment of bacterial diseases is facing twin threats, with increasing bacterial antibiotic resistance and relatively few novel compounds or strategies under development or entering the clinic. Bacteria frequently grow on surfaces as biofilm communities encased in a polymeric matrix. The biofilm mode of growth is associated with 65 to 80% of all clinical infections. It causes broad adaptive changes; biofilm bacteria are especially (10-to 1,000-fold) resistant to conventional antibiotics and to date no antimicrobials have been developed specifically to treat biofilms. Small synthetic peptides with broad-spectrum antibiofilm activity represent a novel approach to treat biofilm-related infections. Recent developments have provided evidence that these peptides can inhibit even developed biofilms, kill multiple bacterial species in biofilms (including the ESKAPE [Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species] pathogens), show strong synergy with several antibiotics, and act by targeting a universal stress response in bacteria. Thus, these peptides represent a promising alternative treatment to conventional antibiotics and work effectively in animal models of biofilm- associated infections.

UR - http://www.scopus.com/inward/record.url?scp=84974574369&partnerID=8YFLogxK

U2 - 10.1128/JB.00017-16

DO - 10.1128/JB.00017-16

M3 - Review article

VL - 198

SP - 2572

EP - 2578

JO - Journal of Bacteriology

JF - Journal of Bacteriology

SN - 0021-9193

IS - 19

ER -